Terapêutica não insulínica da Diabetes Mellitus: mais valias…
Palavras-chave:
nibidor da α-glicosidase, secretogogos, biguanidas, tiazolidinedionas, miméticos das incretinas, inibidores da DPP-4Resumo
A diabetes mellitus (DM) é uma doença crónica de prevalência
crescente. O arsenal terapêutico disponível para tratamento desta
doença tem aumentado significativamente na última década, o
que se traduz na prática clínica por um maior número de opções
terapêuticas e pela necessidade de se tomar decisões cada vez
mais complexas. Os autores apresentam uma revisão do mecanismo de acção, efeitos adversos, contra-indicações, eficácia e
mais valias de cada classe de fármacos.
Downloads
Referências
Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 2003; 92(suppl):50J-60J.
American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2003;26 (suppl 1): S28-S32.
American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care. 2007 Jan;30 Suppl 1:S4-S41.
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287:360-72.
Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005;172(2):213-226. Review
Del Prato S, Bianchi C, Marchetti P. beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev 2007;23(7):518-27. Review
Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137:25-33.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
Koski RR. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus. Diabetes Educ. 2006 ;32(6):869-876. Review.
Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. [Cochrane review]. In: The Cochrane Library; Issue 4, 2004.
Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004;255 (2): 179-187.
Sáenz Calvo A, Fernández Esteban I, Mataix Sanjuán A, Ausejo Segura M, Roqué M, Moher D. [Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis] Aten Primaria 2005; 36(4):183-91. Review. Spanish
Peters AL. Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.Am J Manag Care 2001; 7(3 Suppl):S87-95; quiz S96-7. Review.
Luna B, Feinglos MN.Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001; 63(9):1747-1756.
Tack CJ, Smits P. Thiazolidinedione derivatives in type 2 diabetes mellitus. Neth J Med 2006; 64(6):166-174. Review.
Avandia. In: Physicians’ Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex 2006.
Actos. In: Physicians’ Desk Reference [electronic version]. Greenwood Village, Colo: Thomson Micromedex 2006
Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27:256-263.
Lago RM, Singh PP, Nesto RW.Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 2007; 370(9593):1129-1136. Review.
Donnelly R. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.Int J Clin Pract 2007; 61(7):1160-1169. Epub 2007 May 18. Review.
Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008 Apr; 155(4):712-7. Epub 2008 Feb 21. Erratum in: Am Heart J. 2008; 156(2):255.
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients.Am J Physiol Endocrinol Metab 2007; 292(3):E871-883. Epub 2006 Nov 14.
Fagerberg B, Schuster H, Birketvedt GS, Tonstad S, Ohman KP, Gause-Nilsson I; SIR Study Group. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar. Diab Vasc Dis Res 2007; 4(3): 174-180.
Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, Stoa-Birketvedt G, Tonstad S, Halldórsdóttir S, Gause-Nilsson I. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 2005; 48(9): 1716-1725.
Göke B, Gause-Nilsson I, Persson A; GALLANT 8 Study Group. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diab Vasc Dis Res 2007; 4(3): 204-213.
Ratner RE; The Diabetes Prevention Program Research. An update on the Diabetes Prevention Program. Endocr Pract 2006;12 Suppl 1:20-24. Review.
Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 2005; 27(8): 1181-1195.
Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60 (11):1454-1470. Review.
Meier JJ, Gallwitz B, Salmen S et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88: 2719-2725.
Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144: 5145–5148.
Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145: 2653–9. 2006; 445: 9–18.
Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30 (6): 1487-1493.
Gleeson JM, Berenbeim DM, Gilkin RJ. Incretin mimetics: promising new therapeutic options in the treatment of type 2 diabetes. J Manag Care Pharm. 2005 ; 11 (7 Suppl):S2-13; quiz S14-15.
Hinnen D, Nielsen LL, Waninger A, Kushner P. Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. J Am Board Fam Med. 2006; 19 6):612-620. Erratum in: J Am Board Fam Med 2007; 20(2):240.
Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharm 2006 In press.
Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes.Expert Opin Pharmacother. 2008; 9(10):1705-1720. Review.
Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006; 60(11):1454-1470. Review.
Singh-Franco D, Robles G, Gazze D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29(4):535-562. Review.
Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004; 21(11):1204-1212.
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 ;281 (21): 2005-2012.
Schnell O, Standl E. Impaired glucose tolerance, diabetes, and cardiovascular disease.Endocr Pract 2006;12 Suppl 1:16-19. Review.
Bolen S, Wilson L, Vassy J, Feldman L, Yeh J, Marinopoulos S, et al. Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults with Type 2 Diabetes. Rockville, MD: Agency for Healthcare Research and
Quality; 2007
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M,Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366 (9493): 1279-1289.
Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD; RECORD Study Group. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol 2008; 7:10.
[Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials]Rev Med Suisse. 2007;3(122):1876, 1878-83. Review. French.
Golay A. Metformin and body weight.Int J Obes (Lond). 2008; 32(1):61-72. Epub 2007 Jul 24. Review
Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31(5):845-851. Epub 2008 Jan 25.
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2
diabetes inadequately controlled on metformin alone: a randomized, doubleblind, non-inferiority trial. Diabetes Obes Metab 2007; 9(2):194-205.
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Clin Ther 2006; 28(10): 1556-1568.
Bays H, McElhattan J, Bryzinski BS; GALLANT 6 Study Group. A doubleblind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2007;4(3):181-193
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
